Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L9LS for Malaria Prevention in Kenyan Children
NCT05400655Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of L9LS in malaria, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2022; status: completed.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05400655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400655.